Fresenius

(IN BRIEF) Fresenius Medical Care (FME) has been named the top company in Boston Consulting Group’s (BCG) Gender Diversity Index Germany for 2024, rising from 29th place the previous year. The recognition, featured in Manager Magazin, acknowledges FME’s progress in … Read the full press release →

(IN BRIEF) Fresenius Kabi is addressing the global threat of antimicrobial resistance (AMR), which causes millions of deaths annually, through sustainable manufacturing, improved antibiotic access, and promoting responsible use. During AMR Awareness Week, the company highlighted its commitment to reducing … Read the full press release →

(IN BRIEF) Fresenius Medical Care (FME), a global leader in renal healthcare, has earned a spot at #4 on Massachusetts’ Top 100 Women-Led Businesses list, compiled by The Women’s Edge and The Boston Globe. CEO Helen Giza’s leadership has been … Read the full press release →

(IN BRIEF) Fresenius Medical Care’s subsidiary, Xenios AG, has launched Xenios 2.0, a new system for extracorporeal life support (ECLS) that serves patients from neonates to adults. Approved under the new Medical Device Regulation (MDR), Xenios 2.0 offers advanced safety … Read the full press release →

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release →

(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release →

(IN BRIEF) Wolters Kluwer has nominated Anjana Harve, currently the EVP and CIO at BJ’s Wholesale Club, for a position on its Supervisory Board, pending approval at an Extraordinary General Meeting (EGM) on October 28, 2024. Harve, a seasoned IT … Read the full press release →

(IN BRIEF) At the Annual General Meeting in Frankfurt am Main, shareholders of Fresenius SE & Co. KGaA overwhelmingly approved proposals from the General Partner and the Supervisory Board. Chairman of the Supervisory Board, Wolfgang Kirsch, commended Fresenius’ resilience amidst … Read the full press release →

(IN BRIEF) Fresenius Medical Care (FME), a global leader in renal disease solutions, unveils a pioneering Augmented Reality (AR) application aimed at revolutionizing training for Intensive Care Unit (ICU) nursing staff. The AR glasses, coupled with digital learning modules, offer … Read the full press release →

(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release →

(IN BRIEF) Fresenius Medical Care, a leading provider of products and services for renal diseases, celebrates International Women’s Day by honoring three exceptional employees for their outstanding achievements. Ana Catalina Alvarez Elias, a Research Scientist, has been recognized as an … Read the full press release →

(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release →

(IN BRIEF) Fresenius, a global healthcare group, has appointed an independent advisory board to focus on sustainability issues. Comprising four experts from various fields, the board will support the development of Fresenius’ sustainability strategy. This move reflects Fresenius’ commitment to … Read the full press release →

(IN BRIEF) Fresenius had a strong finish in 2023, with a robust fourth quarter performance. They project accelerated earnings growth in 2024 due to the momentum from their #FutureFresenius initiatives. Achieving their raised outlook for FY/23, the company saw continued … Read the full press release →